Nuclera Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 124


  • Latest Deal Type
  • Series C
  • (In Progress)

  • Investors
  • 17

Nuclera General Information


Developer of an automated construct platform designed to inform off-platform protein scale-up, delivering reliable protein in hand within a certain time. The company offers rapid access to high-quality, soluble, active proteins allowing researchers to accelerate their protein projects, enabling faster success and technology-integrated cell-free protein synthesis and digital microfluidics on smart cartridges that allow rapid progress on protein projects through automated, high-throughput protein access system.

Contact Information

Formerly Known As
Nuclera Nucleics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Corporate Office
  • One Vision Park, Station Road, Impington
  • Cambridge CB24 9NP
  • England, United Kingdom

Nuclera Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nuclera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series C) 10-Oct-2023 000.00 In Progress Generating Revenue
10. Accelerator/Incubator 19-Mar-2024 000.00 Completed Generating Revenue
9. Secondary Transaction - Private 000.00 Completed Generating Revenue
8. Later Stage VC (Series B) 06-Jul-2022 000.00 000.00 00000 Completed Generating Revenue
7. Later Stage VC (Series A) 01-Oct-2019 000.00 0000 0000 Completed Generating Revenue
6. Accelerator/Incubator 22-Feb-2017 00000 Completed Startup
5. Grant 01-Jul-2015 00000 00000 Completed Startup
4. Grant 01-Jul-2014 000.00 00000 Completed Startup
3. Grant 01-May-2014 $167K $837K Completed Startup
2. Accelerator/Incubator $837K Completed Startup
To view Nuclera’s complete valuation and funding history, request access »

Nuclera Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 000.00 000.00 000.00 00.000
Series B 000,000 00.000000 000.00 000.00 000.00 0.000
Ordinary 0,000,000 00.000000 00.0 00.0 00.0 00.000
Ordinary 00,000 00.000000 00 00 00 0.000
Ordinary 39,499 $0.000122 $4.88 $4.88 $4.88 0.53%
Ordinary 250,000 $0.000122 $2.45 $2.45 $2.45 3.38%
To view Nuclera’s complete cap table history, request access »

Nuclera Patents

Nuclera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202404261-D0 High throughput protein expression screening Pending 25-Mar-2024
GB-202404024-D0 High throughput protein expression screening Pending 20-Mar-2024
GB-202403094-D0 Creating nucleic acids for in-vitro protein synthesis Pending 04-Mar-2024
GB-202403101-D0 Creating nucleic acids for in-vitro protein synthesis Pending 04-Mar-2024
GB-202402747-D0 Multi polarity driving for digital microfluidics Pending 27-Feb-2024
To view Nuclera’s complete patent history, request access »

Nuclera Executive Team (6)

Name Title Board Seat Contact Info
Michael Chen Ph.D Co-Founder, Chief Executive Officer & Board Member
Jiahao Huang Ph.D Co-Founder, Chief Financial Officer & Board Member
Gordon McInroy Ph.D Co-Founder, Chief Technology Officer & Board Member
Joseph Bertelsen Chief Commercial Officer
Suzanne Fuld Senior Product Marketing Manager
You’re viewing 5 of 6 executive team members. Get the full list »

Nuclera Board Members (10)

Name Representing Role Since
Barnaby Martin RT Partners Board Member 000 0000
Gordon McInroy Ph.D Nuclera Co-Founder, Chief Technology Officer & Board Member 000 0000
Jiahao Huang Ph.D Nuclera Co-Founder, Chief Financial Officer & Board Member 000 0000
Jonathan Milner Ph.D Self Board Member 000 0000
Joseph Keegan Ph.D Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Nuclera Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nuclera Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Tech Nation Group Accelerator/Incubator 000 0000 000000 0
Amadeus Capital Partners Venture Capital Minority 000 0000 000000 0
British Business Bank Lender/Debt Provider Minority 000 0000 000000 0
Danaher Ventures Corporate Venture Capital Minority 000 0000 000000 0
E Ink Corporation Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Nuclera Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
E Ink (Digital Microfluidics Unit) 12-May-2021 000000000 000.00 Buildings and Property 0000000 0
To view Nuclera’s complete investments history, request access »

Nuclera FAQs

  • When was Nuclera founded?

    Nuclera was founded in 2013.

  • Who is the founder of Nuclera?

    Michael Chen Ph.D, Jiahao Huang Ph.D, and Gordon McInroy Ph.D are the founders of Nuclera.

  • Who is the CEO of Nuclera?

    Michael Chen Ph.D is the CEO of Nuclera.

  • Where is Nuclera headquartered?

    Nuclera is headquartered in Cambridge, United Kingdom.

  • What is the size of Nuclera?

    Nuclera has 124 total employees.

  • What industry is Nuclera in?

    Nuclera’s primary industry is Biotechnology.

  • Is Nuclera a private or public company?

    Nuclera is a Private company.

  • What is Nuclera’s current revenue?

    The current revenue for Nuclera is 00000.

  • How much funding has Nuclera raised over time?

    Nuclera has raised $79.1M.

  • Who are Nuclera’s investors?

    Tech Nation Group, Amadeus Capital Partners, British Business Bank, Danaher Ventures, and E Ink are 5 of 17 investors who have invested in Nuclera.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »